论文部分内容阅读
[目的]研究多处方剂量融合正向调强治疗计划在鼻咽癌放疗中可行性和适用范围。[方法]6例接受调强放疗的鼻咽癌患者,利用Pinnacle6.2适形治疗计划系统,根据剂量分布,调整照射野的方向和处方剂量数,各计划融合后得到优化的正向调强计划。分别与各自在CORVUS6.3计划上优化的逆向治疗计划比较计划肿瘤区(PGTV)和计划临床靶区(PCTV)的剂量分布、危及器官剂量分布和计划临床靶区的适形度。[结果]根据RTOG0225要求,正向计划肿瘤区和危及器官剂量分布符合处方剂量要求,95%PGTV体积的剂量为69.8～70.8Gy,95%PCTV体积的剂量为54.0～55.6Gy,与逆向计划的58.0～60.4Gy比较有显著性差异(P<0.05)。正向调强与逆向调强计划的中位Mu值分别为300和3000,有显著性差异(P<0.05);两者平均治疗时间分别为10min和25min,有显著性差异(P<0.05)。[结论]多处方剂量融合正向调强治疗计划靶区和危及器官剂量分布符合要求,适用于早期鼻咽癌治疗,计划优化和治疗实施时间缩短。
[Objective] To study the feasibility and scope of multi-prescription dose fusion forward modulated therapy in radiotherapy of nasopharyngeal carcinoma. [Methods] Six patients with nasopharyngeal carcinoma receiving intensity modulated radiotherapy were treated with Pinnacle 6.2 conformal treatment planning system. According to the dose distribution, the direction of radiation field and the prescription dose were adjusted. plan. The dose distributions of the planned tumor area (PGTV) and the planned clinical target area (PCTV), respectively, were compared to their respective inverse regimens planned on the CORVUS 6.3 program, compromising the organ dose distribution and planning the conformality of the clinical target area. [Results] According to the requirements of RTOG0225, the dosage of dose of 95% PGTV volume was 69.8-70.8Gy and the dose of 95% PCTV volume was 54.0-55.6Gy, which was consistent with the prescription dose requirement 58.0 ~ 60.4Gy significant difference (P <0.05). The median Mu values of the positive and negative intensity-modulated programs were significantly different between 300 and 3000 (P <0.05). The average treatment time was 10 and 25 min, respectively, with a significant difference (P <0.05) . [Conclusion] The multi-prescription dose fusion forward regimen enhances the planning target area and the dose-at-risk organ, which is suitable for the treatment of early stage nasopharyngeal carcinoma, and the planning optimization and the shortening of the treatment time.